Kristian Reich (K Reich)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 77

Top Topics

Atopic Dermatitis

Top Venues

The British journal of dermatology

Journal of the European Academy of Dermatology and Venereology : JEADV

Dermatology and therapy

American journal of clinical dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

María José Valencia López, Brigitte Stephan, Anna Meineke, Sandra Wolf, Diamant Thaҫi, Ulrich Mrowietz, Valerie Andrees, Stephan Jeff Rustenbach, Kristian Reich, Linus Thalmann, Henriette Bogena, Petra Staubach-Renz, Ralph Michael von Kiedrowski, Matthias Augustin
Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries. Psoriasis (Auckland, N.Z.) 14 (2024)
Kristian Reich, Luca Bianchi, Abdallah Khemis, Julia-Tatjana Maul, Athanasios Tsianakas, Christoph M Schempp, Kim Petersen, Mia M Noergaard, Lluis Puig
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). Dermatology and therapy 14 (2) (2024)
Kristian Reich, Luca Bianchi, Abdallah Khemis, Julia-Tatjana Maul, Athanasios Tsianakas, Christoph M Schempp, Kim Petersen, Mia M Noergaard, Lluis Puig
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). Dermatology and therapy 14 (2) (2024)
Kristian Reich, Luca Bianchi, Abdallah Khemis, Julia-Tatjana Maul, Athanasios Tsianakas, Christoph M Schempp, Kim Petersen, Mia M Noergaard, Lluis Puig
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). Dermatology and therapy 14 (2) (2024)
Kristian Reich, Luca Bianchi, Abdallah Khemis, Julia-Tatjana Maul, Athanasios Tsianakas, Christoph M Schempp, Kim Petersen, Mia M Noergaard, Lluis Puig
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). Dermatology and therapy (2024)
María José Valencia López, Brigitte Stephan, Anna Meineke, Sandra Wolf, Diamant Thaҫi, Ulrich Mrowietz, Valerie Andrees, Stephan Jeff Rustenbach, Kristian Reich, Linus Thalmann, Henriette Bogena, Petra Staubach-Renz, Ralph Michael von Kiedrowski, Matthias Augustin
Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries. Psoriasis (Auckland, N.Z.) 14 (2024)
Kristian Reich, Eric Simpson, Andreas Wollenberg, Robert Bissonnette, Masatoshi Abe, Tracy Cardillo, Jonathan Janes, Luna Sun, Sherry Chen, Jonathan Ian Silverberg
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. The British journal of dermatology 188 (2) (2023)
Kristian Reich, M S de Bruin-Weller, M Deleuran, Brian M Calimlim, N Chen, X Hu, A R Tenorio, Jonathan Ian Silverberg
Higher Levels of Response on Clinical Atopic Dermatitis Severity Measures Are Associated with Meaningful Improvements in Patient-Reported Symptom and Quality of Life Measures: Integrated Analysis of Three Upadacitinib Phase 3 Trials. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Richard G Langley, Howard Sofen, Ignacio Dei-Cas, Kristian Reich, Bardur Sigurgeirsson, Richard Bruce Warren, Carle F Paul, Jacek Cezary Szepietowski, Tsen Fang Tsai, Isabelle Hampele, Ruquan You, Pascal Charef, Charis Papavassilis
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. The British journal of dermatology 188 (2) (2023)
Kristian Reich, M S de Bruin-Weller, M Deleuran, Brian M Calimlim, N Chen, X Hu, A R Tenorio, Jonathan Ian Silverberg
Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Seong Jin Jo, Yu-Huei Huang, Tsen Fang Tsai, Byung-Soo Kim, Kristian Reich, Carine Saadoun, Chia-Ling Chang, Ya-Wen Yang, Sang Woong Youn
Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations. The Journal of dermatology (2023)
Knut Schäkel, Kristian Reich, K Asadullah, Andreas Pinter, Denis Jullien, P Weisenseel, C Paul, M Gomez, S Wegner, Y Personke, F Kreimendahl, Yanqing Chen, J Angsana, M W L Leung, K Eyerich
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Kristian Reich, Eric Simpson, Andreas Wollenberg, Robert Bissonnette, Masatoshi Abe, Tracy Cardillo, Jonathan Janes, Luna Sun, Sherry Chen, Jonathan Ian Silverberg
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. The British journal of dermatology 188 (2) (2023)
Richard G Langley, Howard Sofen, Ignacio Dei-Cas, Kristian Reich, Bardur Sigurgeirsson, Richard Bruce Warren, Carle F Paul, Jacek Cezary Szepietowski, Tsen Fang Tsai, Isabelle Hampele, Ruquan You, Pascal Charef, Charis Papavassilis
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. The British journal of dermatology 188 (2) (2023)
Karoline Jungclaus, Rosa Mascarenhas, Oscar Tellechea, Jeremias L K Reich, Kristian Reich
Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum Contagiosum. Dermatology research and practice 2023 (2023)
Kerstin Wolk, Dagmar Wilsmann-Theis, Katrin Witte, Theresa-Charlotte Brembach, Christian Kromer, Sascha Gerdes, Kamran Ghoreschi, Kristian Reich, Rotraut Mössner, Robert Sabat
Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment. International journal of molecular sciences 24 (2) (2023)
Kerstin Wolk, Dagmar Wilsmann-Theis, Katrin Witte, Theresa-Charlotte Brembach, Christian Kromer, Sascha Gerdes, Kamran Ghoreschi, Kristian Reich, Rotraut Mössner, Robert Sabat
Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment. International journal of molecular sciences 24 (2) (2023)
Kristian Reich, Eric Simpson, Andreas Wollenberg, Robert Bissonnette, Masatoshi Abe, Tracy Cardillo, Jonathan Janes, Luna Sun, Sherry Chen, Jonathan Ian Silverberg
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. The British journal of dermatology 188 (2) (2023)
Kerstin Wolk, Dagmar Wilsmann-Theis, Katrin Witte, Theresa-Charlotte Brembach, Christian Kromer, Sascha Gerdes, Kamran Ghoreschi, Kristian Reich, Rotraut Mössner, Robert Sabat
Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment. International journal of molecular sciences 24 (2) (2023)
Jonathan Ian Silverberg, April W Armstrong, Andrew Blauvelt, Kristian Reich
Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids. American journal of clinical dermatology (2023)
Jonathan Ian Silverberg, April W Armstrong, Andrew Blauvelt, Kristian Reich
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids. American journal of clinical dermatology (2023)
Kristian Reich, Eva Cullen, Mark Weinberg
Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence? The British journal of dermatology 187 (4) (2022)
Eric L Simpson, Robert Bissonnette, Amy S Paller, Brett A King, Jonathan Ian Silverberg, Kristian Reich, Jacob P Thyssen, Helen Doll, Luna Sun, Amy M DeLozier, Fabio P Nunes, Lawrence F Eichenfield
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis. The British journal of dermatology 187 (4) (2022)
Alexander Nast, Corinna Dressler, Christopher Schuster, Daniel Saure, Matthias Augustin, Kristian Reich
Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review. Skin health and disease 3 (1) (2022)
Kristian Reich, K B Gordon, Bruce E Strober, R G Langley, M Miller, Y-W Yang, Y-K Shen, Y You, Y Zhu, P Foley, Andrew Blauvelt
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (12) (2022)
Johannes Geier, Steffen Schubert, Kristian Reich, Christoph Skudlik, Barbara K Ballmer-Weber, Randolf Brehler, Elke Weisshaar, Wolfgang Uter, null null
Contact sensitization to essential oils: IVDK data of the years 2010-2019. Contact dermatitis 87 (1) (2022)
Alexander Nast, Corinna Dressler, Christopher Schuster, Daniel Saure, Matthias Augustin, Kristian Reich
Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review. Skin health and disease 3 (1) (2022)
Matthias Augustin, Kristian Reich, Paul Yamauchi, Andreas Pinter, Jerry Bagel, Swapnil Dahale, Ruquan You, Gerard Bruin, Jimena Djimopoulos, Bertrand Paguet, Pascal Charef, Manmath Patekar, Deborah Keefe
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. The British journal of dermatology 186 (6) (2022)
Kristian Reich, L Iversen, Lluis L Puig, J Lambert, Ulrich Mrowietz, K Kaplan Saday, R B Warren
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (8) (2022)
Kristian Reich, Xenophon Baraliakos, Laura C Coates, Boni E Elewski, Weibin Bao, Torben Kasparek, Corine Gaillez, Effie Pournara, Maher Aassi, Chiara Perella, Alice B Gottlieb
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis. The British journal of dermatology 187 (3) (2022)
Thomas Bieber, Kristian Reich, Carle F Paul, Yuichiro Tsunemi, Matthias Augustin, Jean-Philippe Lacour, Pierre-Dominique Ghislain, Yves Dutronc, Ran Liao, Fan E Yang, Dennis Brinker, Amy M DeLozier, Eric Meskimen, Jonathan M Janes, Kilian Eyerich, null null
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). The British journal of dermatology 187 (3) (2022)
Eric L Simpson, Joseph Frank Merola, Jonathan Ian Silverberg, Kristian Reich, Richard B Warren, Delphine Staumont-Sallé, Giampiero Girolomoni, Kim A Papp, Marjolein de Bruin-Weller, Jacob P Thyssen, Rebecca Zachariae, Christiana K Olsen, Andreas Wollenberg
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. The British journal of dermatology 187 (6) (2022)
A B Gottlieb, J F Merola, Kristian Reich, F Behrens, P Nash, Christopher Ernest Maitland Griffiths, W Bao, P Pellet, L Pricop, I B McInnes
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. The British journal of dermatology (2021)
Kristian Reich, Kenneth B Gordon, Bruce E Strober, April W Armstrong, Megan Miller, Y K Shen, Y You, C Han, Y W Yang, Peter Foley, Christopher Ernest Maitland Griffiths
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. The British journal of dermatology (2021)
Teresa Tsakok, T Rispens, P Spuls, Alexander Nast, Catherine H Smith, Kristian Reich
Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2) (2021)
Kilian Eyerich, Peter Weisenseel, Andreas Pinter, Knut Schäkel, Khusru Asadullah, Sven Wegner, Ernesto J Muñoz-Elias, Holger Bartz, Friedmann J H Taut, Kristian Reich
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ open 11 (9) (2021)
Kristian Reich, April W Armstrong, Peter Foley, Michael Song, Megan Miller, Y K Shen, Yin You, Chenglong Han, Kenneth B Gordon
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. American journal of clinical dermatology 21 (6) (2021)
Dagmar Wilsmann-Theis, Christian Kromer, S Gerdes, C Linker, N Magnolo, R Sabat, Kristian Reich, R Mössner
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS). Journal of the European Academy of Dermatology and Venereology : JEADV 35 (10) (2021)
D Thaci, Stefano Piaserico, R B Warren, Aditya Kumar Gupta, W Cantrell, Z Draelos, P Foley, A Igarashi, R G Langley, A Asahina, M Young, M Falqués, I Pau-Charles, A M Mendelsohn, S J Rozzo, Kristian Reich
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). The British journal of dermatology 185 (2) (2021)
Kristian Reich, J B Hansen, Lluis L Puig, Maria-Polina Konstantinou, R B Warren
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (10) (2021)
Kenneth B Gordon, M Lebwohl, Kim A Papp, H Bachelez, J J Wu, R G Langley, Andrew Blauvelt, B Kaplan, M Shah, Y Zhao, R Sinvhal, Kristian Reich
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. The British journal of dermatology (2021)
Anna K Langenbruch, Nicole Zander, Natalia Kirsten, Kristian Reich, R von Kiedrowski, K Strömer, Ulrich Mrowietz, Matthias Augustin
Quality of psoriasis care in Germany - results from the nationwide health care studies PsoHealth 2004-2017. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (7) (2021)
Andrew Blauvelt, April W Armstrong, Richard G Langley, Kurt Gebauer, Diamant Thaҫi, Jerry Bagel, Lyn C Guenther, Carle F Paul, Bruce Randazzo, Susan Flavin, Ming-Chun Hsu, Yin You, Kristian Reich
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. The Journal of dermatological treatment (2021)
Ulrich Mrowietz, R B Warren, C L Leonardi, D Saure, H Petto, S Hartz, M Dossenbach, Kristian Reich
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (5) (2021)
A Leutz, Andreas Pinter, D Thaçi, Matthias Augustin, C Schuster, K Fotiou, H P Hundemer, D Saure, Ulrich Mrowietz, Kristian Reich
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. The British journal of dermatology 184 (3) (2020)
Andrew Blauvelt, Carle F Paul, Peter Cornelis Maria van de Kerkhof, R B Warren, A B Gottlieb, R G Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, Kristian Reich
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. The British journal of dermatology 184 (4) (2020)
Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn C Guenther, Melinda J Gooderham, Laura K Ferris, Christopher E M Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim A Papp
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and therapy 10 (3) (2020)
Kristian Reich, Kim A Papp, April W Armstrong, Y Wasfi, S Li, Y K Shen, B Randazzo, M Song, Alexa B Kimball
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. The British journal of dermatology 180 (5) (2020)
Andreas Pinter, M Hoffmann, Kristian Reich, Matthias Augustin, K Kaplan, S D Gudjónsdóttir, T Delvin, Ulrich Mrowietz, null null
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE). Journal of the European Academy of Dermatology and Venereology : JEADV 35 (3) (2020)
R B Warren, Y José Manuel Carrascosa, E Fumero, A Schoenenberger, M G Lebwohl, Jacek Cezary Szepietowski, Kristian Reich
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (4) (2020)
K B Gordon, R B Warren, A B Gottlieb, Andrew Blauvelt, D Thaçi, C Leonardi, Y Poulin, M Boehnlein, F Brock, C Ecoffet, Kristian Reich
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). The British journal of dermatology 184 (4) (2020)
Julien Seneschal, J-P Lacour, A Bewley, M Faurby, C Paul, G Pellacani, C De Simone, L Horne, A Sohrt, Matthias Augustin, E Hammond, Kristian Reich
A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). Journal of the European Academy of Dermatology and Venereology : JEADV 34 (11) (2020)
Kristian Reich, A Körber, Ulrich Mrowietz, Michael Sticherling, C Sieder, J Früh, T Bachhuber
Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study. The British journal of dermatology 184 (5) (2020)
T Bieber, Jacob Pontoppidan Thyssen, Kristian Reich, E L Simpson, N Katoh, Antonio Torrelo, M De Bruin-Weller, D Thaci, R Bissonnette, M Gooderham, J Weisman, F Nunes, D Brinker, M Issa, K Holzwarth, M Gamalo, E Riedl, J Janes
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2) (2020)
Kristian Reich
A new treatment option for paediatric psoriasis. The British journal of dermatology 183 (4) (2020)
R B Warren, J B Hansen, Kristian Reich, C Paul, Lluis L Puig
Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2) (2020)
Andrew Blauvelt, Kim A Papp, A Gottlieb, A Jarell, Kristian Reich, C Maari, K B Gordon, L K Ferris, R G Langley, Y Tada, R G Lima, H Elmaraghy, G Gallo, L Renda, S Y Park, R Burge, J Bagel, null null
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. The British journal of dermatology 182 (6) (2020)
Kristian Reich, C Sorbe, L Griese, Jeremias L K Reich, Matthias Augustin
The value of subcutaneous vs. oral methotrexate: real-world data from the German psoriasis registry PsoBest. The British journal of dermatology 184 (4) (2020)
Kristian Reich, J Sullivan, P Arenberger, S Jazayeri, Ulrich Mrowietz, Matthias Augustin, Boni E Elewski, R You, P Regnault, J A Frueh
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. The British journal of dermatology 184 (3) (2020)
Neuza da Silva, Matthias Augustin, Anna Langenbruch, Ulrich Mrowietz, Kristian Reich, Diamant Thaçi, Wolf-Henning Boehncke, Natalia Kirsten, Alexandra Danckworth, Rachel Sommer
Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. PloS one 15 (7) (2020)
Alexa B Kimball, T Kerbusch, F van Aarle, P Kulkarni, Q Li, Andrew Blauvelt, Kim A Papp, Kristian Reich, D Montgomery
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. The British journal of dermatology 182 (1) (2019)
Matthias Augustin, R Sommer, N Kirsten, A Danckworth, M A Radtke, Kristian Reich, D Thaci, W H Boehncke, Anna K Langenbruch, U Mrowietz
Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. The British journal of dermatology 181 (2) (2019)
Kristian Reich, L Puig, J C Szepietowski, Carle F Paul, J P Lacour, A Tsianakas, C Sieder, M Rissler, E Pournara, R Orsenigo
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. The British journal of dermatology 182 (2) (2019)
Matthias Augustin, D Thaci, K Eyerich, A Pinter, M Radtke, F Lauffer, U Mrowietz, S Gerdes, D Pariser, M Lebwohl, C Sieder, N Melzer, Kristian Reich
Continued treatment with secukinumab is associated with high retention or regain of response. The British journal of dermatology 182 (1) (2019)
Kristian Reich, Peter Foley, Chenglong Han, Sean McElligott, Erik Muser, Nan Li, April W Armstrong
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. The Journal of dermatological treatment 31 (6) (2019)
Kristian Reich, J L K Reich, T M Falk, N Blödorn-Schlicht, Ulrich Mrowietz, R von Kiedrowski, C Pfeiffer, J Niesmann, Y Frambach, R B Warren
Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways. The British journal of dermatology 181 (4) (2019)
Kristian Reich, Matthias Augustin, D Thaçi, A Pinter, A Leutz, C Henneges, E Schneider, A Schacht, M Dossenbach, Christina Sorbe
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. The British journal of dermatology 182 (4) (2019)
Kristian Reich, Michael Song, Shu Li, Jingzhi Jiang, Sang Woong Youn, Tsen Fang Tsai, Yong Beom Choe, Yu-Huei Huang, Kenneth B Gordon
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. The Journal of dermatology 46 (12) (2019)
Rotraut Mössner, D Wilsmann-Theis, V Oji, P Gkogkolou, S Löhr, P Schulz, A Körber, J C Prinz, R Renner, K Schäkel, L Vogelsang, K-P Peters, S Philipp, Kristian Reich, H Ständer, A Jacobi, A Weyergraf, K Kingo, S Kõks, S Gerdes, K Steinz, T Schill, K G Griewank, M Müller, S Frey, L Ebertsch, S Uebe, M Sticherling, H Sticht, Ulrike Hüffmeier
The genetic basis for most patients with pustular skin disease remains elusive. The British journal of dermatology 178 (3) (2018)
Andrew Blauvelt, Kristian Reich, Kim A Papp, A B Kimball, M Gooderham, S K Tyring, R Sinclair, D Thaçi, Q Li, N Cichanowitz, S Green, C La Rosa
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. The British journal of dermatology 179 (3) (2018)
Matthias Augustin, A Langenbruch, M Gutknecht, Kristian Reich, A Körber, D Maaßen, U Mrowietz, D Thaçi, R von Kiedrowski, M A Radtke
Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. The British journal of dermatology 179 (6) (2018)
Kim A Papp, C L Leonardi, Andrew Blauvelt, Kristian Reich, N J Korman, M Ohtsuki, Carle F Paul, S Ball, G S Cameron, J Erickson, L Zhang, L Mallbris, C E M Griffiths
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). The British journal of dermatology 178 (3) (2018)
R B Warren, Kristian Reich, R G Langley, Bruce E Strober, D Gladman, A Deodhar, T Bachhuber, W Bao, E Altemeyer, S Hussain, J Safi
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. The British journal of dermatology 179 (5) (2018)
Andrew Blauvelt, C E M Griffiths, M Lebwohl, U Mrowietz, Lluis L Puig, S Ball, L Zhang, E Edson-Heredia, M Warner, B Zhu, C-Y Lin, E Nikaï, D Dey, L Mallbris, Kristian Reich
Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. The British journal of dermatology 177 (2) (2017)
Michael Sticherling, U Mrowietz, Matthias Augustin, D Thaçi, N Melzer, C Hentschke, J Kneidl, C Sieder, Kristian Reich
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. The British journal of dermatology 177 (4) (2017)
Kristian Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm, S Hartz, Carle F Paul, null null
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. The British journal of dermatology 177 (4) (2017)
Kristian Reich, I Zschocke, H Bachelez, E M G J de Jong, Paolo Gisondi, Lluis L Puig, R B Warren, C Ortland, U Mrowietz, null null
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). The British journal of dermatology 177 (1) (2017)